- Home
- QCRH vs TRVI Comparison
QCRH vs TRVI Comparison
Compare QCRH & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- TRVI
- Stock Information
- Founded
- QCRH 1993
- TRVI 2011
- Country
- QCRH United States
- TRVI United States
- Employees
- QCRH N/A
- TRVI N/A
- Industry
- QCRH Major Banks
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- QCRH Finance
- TRVI Health Care
- Exchange
- QCRH Nasdaq
- TRVI Nasdaq
- Market Cap
- QCRH 1.3B
- TRVI 1.1B
- IPO Year
- QCRH 1993
- TRVI 2019
- Fundamental
- Price
- QCRH $72.03
- TRVI $9.95
- Analyst Decision
- QCRH Buy
- TRVI Strong Buy
- Analyst Count
- QCRH 3
- TRVI 9
- Target Price
- QCRH $88.83
- TRVI $20.72
- AVG Volume (30 Days)
- QCRH 104.2K
- TRVI 2.3M
- Earning Date
- QCRH 10-22-2025
- TRVI 11-05-2025
- Dividend Yield
- QCRH 0.32%
- TRVI N/A
- EPS Growth
- QCRH N/A
- TRVI N/A
- EPS
- QCRH 6.63
- TRVI N/A
- Revenue
- QCRH $322,873,000.00
- TRVI N/A
- Revenue This Year
- QCRH N/A
- TRVI N/A
- Revenue Next Year
- QCRH $14.12
- TRVI N/A
- P/E Ratio
- QCRH $11.28
- TRVI N/A
- Revenue Growth
- QCRH N/A
- TRVI N/A
- 52 Week Low
- QCRH $60.83
- TRVI $2.36
- 52 Week High
- QCRH $96.08
- TRVI $10.16
- Technical
- Relative Strength Index (RSI)
- QCRH 30.07
- TRVI 67.14
- Support Level
- QCRH $75.06
- TRVI $9.30
- Resistance Level
- QCRH $77.48
- TRVI $10.16
- Average True Range (ATR)
- QCRH 1.66
- TRVI 0.49
- MACD
- QCRH -0.60
- TRVI 0.08
- Stochastic Oscillator
- QCRH 0.00
- TRVI 90.57
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.